Cocrystal Pharma Q3 2021 Earnings Report
Key Takeaways
Cocrystal Pharma reported no revenues for Q3 2021 compared to $489,000 in Q3 2020. R&D expenses were $2.2 million, and G&A expenses were $1.8 million. The net loss for the quarter was $3.9 million, or $0.04 per share.
Focusing on COVID-19 antiviral development programs with the goal of beginning first-in-human clinical studies in 2022.
Expecting comments from the FDA by mid-December on the pre-IND briefing package for the intranasal/pulmonary-delivered SARS-CoV-2 protease inhibitor CDI-45205.
Anticipating selecting a lead candidate from novel SARS-CoV-2 protease inhibitors for oral administration by year-end 2021.
Expecting patient enrollment in the Phase 1 trial for the novel PB2 inhibitor CC-42344 for pandemic and seasonal influenza A to begin in early 2022.
Cocrystal Pharma
Cocrystal Pharma
Forward Guidance
The Company expects R&D expenses to increase in the fourth quarter of 2021 due to the advancement of our influenza A program into clinical trials and progress with our pre-clinical COVID-19 program toward clinical development.